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At Risk for Huntington's Disease
HD is a genetically caused brain disorder that causes uncontrollable bodily movements and robs
people's ability to walk, talk, eat, and think. The final result is a slow, ugly death. Children of parents
with HD have a 50-50 chance of inheriting the disease. There is no cure or treatment.
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California stem cell agency approves $19 million
clinical trial project as Huntington’s disease families
‘change the course of science’
Adult stem cells designed to rescue brain cells from death in
Huntington’s disease patients could enter human testing in
the next three to four years, thanks to a $19 million grant to
an HD research team at the University of California, Davis
(UC Davis), from the California Institute for Regenerative
Medicine (CIRM).
If successful, this first-ever stem cell clinical trial for
Huntington’s could pave the way for a possible treatment of
the devastating disorder.
At a public meeting July 26, the oversight board of the $3
billion stem cell agency announced the award to the lab of
researcher Jan Nolta, Ph.D., a recognized specialist in
mesenchymal (pronounced “meh-zen-KI-mal”) stem cells
(MSC), and her collaborator Vicki Wheelock, M.D., a
neurologist and the director of the Huntington’s Disease
Society of America’s Center for Excellence for Family
Services and Research at UC Davis.
Dr. Nolta aims to introduce MSCs, which act as natural
“paramedics” in the body, into the brains of symptomatic
HD patients to test for safety and tolerability. The trial doses
will be made from a sample of MSCs extracted from a
healthy donor.
MSCs produce a so-called “fertilizer for the brain” (BDNF,
brain-derived neurotrophic factor), whose levels plummet
drastically when someone has HD. Dr. Nolta and her team
have engineered MSCs to produce higher levels of BDNF in
an attempt to help HD-damaged neurons recover and avoid
death, thus slowing, halting, or perhaps even reversing the
course of HD.
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Dr. Nolta’s collaborator Gary Dunbar, Ph.D., of Central
Michigan University, has already demonstrated that these
MSCs mostly stop symptoms in transgenic mice that have
been given the abnormal HD gene.
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The Nolta-Wheelock grant was one of eight CIRM grants
totaling $151 million to labs seeking treatments for
debilitating or fatal diseases, including Lou Gehrig’s disease,
cancer, heart disease, and spinal cord injuries. The awards
were the second largest research round in CIRM history. In
2009 the agency granted more than $200 million to
researchers.
With a score of 87/100, the Nolta-Wheelock grant ranked
highest in the state.
“We’re just so glad that we didn’t let the community down,”
Dr. Nolta told HD activist Melissa Biliardi on The HD View
internet radio program on July 23 in anticipation of the
expected award.
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In this same round UC Davis received two other grants – to
seek treatments for peripheral artery disease and
osteoporosis – that Dr. Nolta will help oversee in her role as
the director of the UC Davis stem cell program and the
university’s Institute for Regenerative Cures (IRC), which
has nearly 150 affiliated faculty researchers.
“People are hopeful, truly hopeful for the first time,” Judy Roberson, the
former president of the Northern California Chapter of the Huntington’s
Disease Society of America (HDSA) and the widow of an HD victim, said
after the CIRM announcement. “This is a nightmarish, cruel disease in
every way but now, thanks to CIRM, we are turning the dream of a stem
cell therapy trial into a reality. Research means hope for people with this
disease, but research costs money. CIRM has given us all hope.”
The trial’s proposed timeline

CIRM will grant the $19 million over four years, the
proposed timeline of the clinical trial project. Most of the
money will cover charges such as surgeries, operating room
and hospital costs, MRI scans, and other items related to the
actual trial.
According to the proposal, the UC Davis team will spend the first year
testing the safety of MSCs in healthy non-human primates. This stage of
the project will help the team secure the necessary approval for human
testing from the U.S. Food and Drug Administration (FDA), which
regulates clinical trials.
In the project’s second year the team hopes to enroll at least 26 early-stage
HD patients in an observational study, including motor and psychiatric
tests and MRI brain scans, to obtain basic measurements of their health
for comparison with readings to be taken during the clinical trial.
At the start of the third year, if all regulatory approvals have been obtained
as planned, the patients will receive a single, direct injection of the MSCs
into each side of their brains (a bilateral intrastriatal injection). A special
neurosurgical team, which will include experts from the University of
California, San Francisco, will bore a tiny hole into the skull to insert a tiny
cathether to deliver the cells. Direct insertion is necessary because of the
blood/brain barrier, which allows few medications to enter the brain.
Patients will have part of their heads shaved. However, their hair should
grow back, and the holes will heal over.
Half of the patients will receive MSCs with the extra BDNF-producing
capability, while the other half will receive a placebo, MSCs without that
capability.
Trial participants will receive dosages in groups and on a staggered
schedule, with each successive group receiving a higher amount of the
MSCs.
The remainder of the trial will primarily check for the safety of the MSCs.
As a secondary goal, the scientists and physicians will also look for
alleviation of symptoms and evidence that the MSCs are improving the
health of the brain.
This first step in the trial is known as Phase I. If the MSCs prove safe, the
team would seek funding for Phases II and III to fully measure the cells’
efficacy.
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All of these plans must receive formal approval from UC Davis’s internal
review board and then the FDA, after which full details will become
available for potential trial participants.
A brief history of stem cells

To understand Dr. Nolta’s work we must travel back in time
to explore the roots of today’s revolution in stem cell
research.
Stem cells became a hot topic in the first decade of the 21st
century because of the controversy over one type: embryonic
stem cells. However, stem cell research long predates this
controversy.
Recall that a stem cell has a very important property: it can
make cells that eventually become another type of cell such
as a muscle cell, skin cell, or brain cell (neuron).
Stem cells help our bodies regenerate lost or worn tissue and
components such as our blood, liver, and skin.
Humans have understood the idea of regeneration since
ancient times, and scientists first started discussing the
concept of stem cells in the mid-1800s. Scientists first
discovered stem cells in mice bone marrow in the early
1960s.
The very first stem cell therapy (treatment) in humans took
place in 1968 with the successful bone marrow transplant for
a leukemia patient whose marrow donor was an identical
twin. This type of transplant helps the patient because bone
marrow contains stem cells that produce new blood cells.
Because of stem cell research, other kinds of transplantation
and tissue regeneration have become possible.
Over the last few decades, scientists have identified other
types of stem cells, including those that produce neurons.
Stem cell research is now burgeoning around the world.
Scientists use stem cells both to understand human biology
and to seek therapies for diseases and traumas.
In August 2001, President George W. Bush stopped federal
funding for new embryonic stem cell research because of his
belief, shared by a good number of Americans, that such
research destroyed human life (the embryo from which the
stem cells were taken) and was therefore immoral. In
California Bush’s restrictions spurred a successful movement
to pass a 2004 ballot initiative, Proposition 71, that skirted
the president’s order with state-level funding, created CIRM,
and catapulted the state into global leadership in stem cell
research.
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In recent years, however, new discoveries have lessened the
controversy about stem cells. Scientists have made many
advances using adult stem cells – those extracted from a
living human being without any risk. In 2006 researchers
achieved another milestone that reduced the need for
embryonic stem cells: they could now take cells from the
skin or other parts of the body and reprogram them into a
stem cell.

Dr. Alvin King of the University of California, Irvine, displays a neural
stem cell on the screen of a microscope (photo by Gene Veritas).

The MSCs, Dr. Nolta’s focus for the past 25 years, are adult
stem cells. Everyone has MSCs. They are found in the bone
marrow, as well as in fat, dental tissue, and the umbilical
cord. They can make bone, tendons, ligaments, and other
connective tissues. MSCs grow well in lab conditions,
making them a prime candidate for research.
Along with other scientists, in recent years Dr. Nolta and
Leslie Thompson, Ph.D., of the University of California,
Irvine, another CIRM grantee, began employing stem cells in
Huntington’s research. Besides MSCs, HD researchers use
human embryonic stem cells, human induced pluripotent
stem cells, neural stem cells, and others.
In Dr. Nolta’s assessment, MSCs appear to have especially
great potential in treating HD because of their abilities as the
body’s “paramedics.” This potential is described in detail
below.
From child scientist to MSC expert

Dr. Nolta’s path to the potentially historic MSC HD clinical
trial began in childhood and took shape in the midst of the
stem cell revolution.
“I think I was probably born a scientist,” she told me during
a May 2011 visit to her lab on the occasion of the HDSA
curehd.blogspot.com/2012/08/california-stem-cell-agency-approves-19.html
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Northern California Chapter’s annual convention. “I was the
kid that was out in the yard investigating bugs and watching
eggs hatch and feeding baby animals that were rescued and
trying to understand how caterpillars went through the
chrysalis form and came out as moths and butterflies.”
Raised by a single working mom in the small northern
California town of Willows and depending on grants and
waitressing for her college education, Dr. Nolta received a
degree in biology from Sacramento State University in 1984.
After graduation Dr. Nolta took M.A.-level science courses at
UC Davis and volunteered in a lab. “We could take stem cells
from the bone marrow and culture them,” she recalled.
“There was this ‘magical’ potion that we could put them in
and culture them for just a few days and could watch them
divide and grow into blood cells. I wanted to secretly keep
the cultures growing and study them.
“Where I fell in love with mesenchymal stem cells was in
1987. We started doing long-term bone marrow cultures,
and there’s a component that grows out when you take a
marrow aspirate from a human being that’s a mono-layer of
broad, flat cells. We used to call those the marrow-stromal
cells. They later got renamed to mesenchymal stem cells due
to their potentiality and all that they can do.”
Dr. Nolta learned that MSCs could assist greatly in gene
therapy. Also known as cellular therapy, gene therapy
involves the use or alteration of genes to treat disease. Dr.
Nolta was impressed with MSCs’ strong ability to assimilate
and deliver gene therapy products.
“I realized very quickly that we could engineer them to even
better support the other cells in the body,” she explained.
To deepen her knowledge of stem cells and MSCs, Dr. Nolta
enrolled in the Ph.D. program in molecular microbiology at
the University of Southern California under the mentorship
of Dr. Donald Kohn, a specialist in pediatric bone marrow
transplantation. At Children’s Hospital Los Angeles she
assisted in his pioneering work on bubble baby syndrome,
AIDS, and other conditions.
From this experience Dr. Nolta learned the techniques of
gene therapy, growing stem cells, and applying stem cell
therapies in the clinic. With Dr. Kohn’s team, she performed
the first cord blood gene therapy trial for infants born with
bubble baby syndrome, a type of serious immune deficiency.
In 2002 the Washington University School of Medicine in St.
Louis, one of the nation’s top medical schools, recruited Dr.
Nolta to help build its programs in gene therapy and stem
curehd.blogspot.com/2012/08/california-stem-cell-agency-approves-19.html
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cell research. There she continued her work on gene therapy
and MSCs and collaborated with her close colleague Gerhard
Bauer, Ph.D., in the establishment of a GMP (good
manufacturing practice) facility, a highly advanced lab
crucial for producing cell and gene therapies.
The power of grassroots advocacy
However, the future of stem cell research lay in California. In
2007 UC Davis lured Dr. Nolta back to her home state to
direct its stem cell programs under the umbrella of the
brand-new IRC, the Institute for Regenerative Cures. CIRM
awarded UC Davis $21 million to construct the IRC and its
state-of-the art GMP facility. UC Davis contributed $40
million to the project.
With little knowledge of Huntington’s disease, Dr. Nolta had
no plans to include it in her research program at the IRC
when she was recruited.
Around the state, however, HD advocates were telling their
stories of the desperate need for treatments at the public
hearings of the CIRM oversight board. They pushed hard for
the CIRM to back HD research.

UC Davis stem cell program manager Geralyn Annett (left), HD patient
Sharon Shaffer, Alexa Shaffer, and Dr. Nolta advocating for HD
research at a CIRM board meeting at UC San Diego in 2008 (photo by
Gene Veritas)

During her recruitment trip to UC Davis, Dr. Nolta met Dr.
Wheelock of the HDSA Center of Excellence.
“Have you ever considered using stem cells to treat
Huntington’s disease?” asked Dr. Wheelock as she rode with
Dr. Nolta in an elevator.
“You know, for the last 20 years, I have been researching
how to use stem cells to treat every part of the body except
curehd.blogspot.com/2012/08/california-stem-cell-agency-approves-19.html
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the brain,” Dr. Nolta responded, citing the critical hurdle of
the blood/brain barrier.
“The families impacted by Huntington’s disease are truly
remarkable,” Dr. Wheelock rejoined. “I’d love to introduce
you to them.”
That conversation spurred Dr. Nolta to take a scientific
interest in HD. More importantly, meeting the families
deeply moved her. She decided to act.
With initial financial backing from HD advocates from the
Sacramento area and elsewhere, Dr. Nolta delved into a
project to find a way to use MSCs to combat HD.
Dr. Nolta used her early findings to apply for a grant from
CIRM. In 2009 the agency awarded her lab $2.7 million to
study the use of genetically reengineered MSCs to block HD
at its genetic roots, first in lab dishes, then in mice
(explained below).
During our interview at the IRC, Dr. Nolta pointed to the
photographs of HD advocates on her desk.
“They change the course of what scientists do,” she said,
breaking into tears. “My life was forever changed.”
In all, local fundraising efforts have provided some
$100,000 for Dr. Nolta’s work. Donations have included
$15,000 from the Deshalamar foundation and $40,000 from
Team KJ, an Illinois initiative in support of Kara Jean
Fleming, a 40-year-old HD patient. The Joseph P. Roberson
Foundation, named for the deceased husband of Judy
Roberson, has also supported Dr. Nolta’s work. Many other
donors, large and small, have also contributed.
Watching the paramedics in action
With the new $19 million CIRM grant – the largest in Dr.
Nolta’s career – she and the UC Davis hope to set their MSC
research on the path to a treatment.
The MSCs’ many attributes make them attractive for treating
HD.
“They’re very social,” Dr. Nolta explained as she played a
highly magnified video in which the MSCs appeared to swim
and greet one another like people playing in a swimming
pool. “They like to interact with other cells.”
The MSCs also move around the body with great facility, Dr.
Nolta added. They can project little tubes, called
nanotubules, that tunnel into cells and inject them with
curehd.blogspot.com/2012/08/california-stem-cell-agency-approves-19.html
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necessary items such as proteins and mitochondria, the
powerhouses of the cell.
“It’s like giving a cell new batteries,” Dr. Nolta explained.
“They just open up a nanotubule and put the new
component into the other cell. So that’s why we call them
paramedics. It’s like they’re going around with tool kits to
repair the other cells…. They like to check out other cells, to
see if they’re healthy. They can change what they produce
from what they sense from the environment and from the
other cells. They just become like little factories.”
“They almost look like living organisms,” I observed.
“They are,” Dr. Nolta said. “They’re alive.”
(Watch the video below to see the MSCs in action.)

Mesenchymal Stem Cells in Action
(narrated by Dr. Jan Nolta)
from Gene Veritas

02:29

Mesenchymal Stem Cells in Action (narrated by Dr. Jan
Nolta) from Gene Veritas on Vimeo.
The MSCs’ sociability results in part from the fact that
damaged or sick cells and neurons put out “distress signals”
that spur the paramedics into action, Dr. Nolta continued.
The same process occurs in the brain, she added. In mice
that carry the human Huntington’s gene and have HD-like
symptoms, MSCs injected into their brains migrated to the
areas of damage.
Transplantations of human tissue often trigger a rejection by
the immune systems of the recipients, requiring them to take
anti-rejection drugs sometimes for the rest of their lives.
This does not occur with MSCs, Dr. Nolta said.
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“That’s the beauty of them,” she said. “They’re transplanted
from one patient to the next with really no regard to tissue
matching. They actually shelter themselves from the
immune system through some of the things that they
secrete. We think that’s part of their natural function in the
body.
“When there’s a wound or a heart attack or some kind of
ischemic event, a stroke, they can go to that area, and they
want to cause the tissue to heal without scarring. That’s part
of their innate mission. They don’t want the immune system
to see it while it’s getting fixed up, because you could start
making auto-antibodies to that damaged tissue, and then
you would destroy that tissue. We think that the MSC just go
to the scene of the injury and keep the immune system at
bay while they’re doing their remodeling. It’s kind of like
keeping everybody out of a construction site.”
The goal: restoring neurons and connections
According to Dr. Nolta, the MSCs secrete substances that
help restore the vital connections between neurons. Such
connections are lost in HD. Additionally, in secreting BDNF
and other brain growth factors, the MSCs can help damaged
neurons recover. She likened this scenario to a chain of
Christmas lights that, missing a bulb, will go out. Restoring
the bulb – a healthy neuron – gets the whole chain working
again.
In the case of the proposed clinical trial, the UC Davis team
will ramp up the MSCs’ capability to provide BDNF. In mice
tests, they have increased that capability by a hundredfold.
The big question, Dr. Nolta told me in an interview on July
30, 2012, is this: how effective will MSCs prove in helping
the entire striatum, an area of the brain deeply compromised
by HD and where the MSCs will be injected?
“The MSCs can secrete huge amounts of BDNF, so that
might be effective” in helping to restore the striatum, she
said.
Attacking HD’s genetic roots
If the MSC BDNF trial proves successful, the UC Davis team
could use another up-and-coming tool for combatting HD:
RNA interference.
In designing a substance known as a small interference RNA
molecule (siRNA), other researchers have already
reducedthe amount of harmful huntingtin protein in the
brains of test animals. A similar approach, known as
antisense, has demonstrated similar results. Both
curehd.blogspot.com/2012/08/california-stem-cell-agency-approves-19.html
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approaches should enter clinical trials within the next few
years, if not sooner.
Still in the early stages of this aspect of their research, Dr.
Nolta and her UC Davis HD team have discovered a way to
deliver siRNA into cells in a dish using MSCs.
Some researchers are examining ways to implant new
neurons or fetal-striatal stem cells into patients’ brains to
repair the damage caused by HD. However, Dr. Nolta
pointed out that those cells could become affected by HD.
The use of siRNA could protect those and other cells from
HD. Dr. Nolta has photos and video of the MSC nanotubules
transferring siRNA into other cells. Her lab is now testing
MSC siRNA in mice.
Controlling the huntingtin gene and protein effectively is the
“holy grail” of HD research because it would allow genepositive, non-symptomatic people like me to take a
preventative treatment.
‘A super, super clean place’
Although the human brain has MSCs, in HD people those
MSCs make the same mutant huntingtin as the other cells in
the brain and, indeed, in the rest of the body. Compromised
in this manner, the MSCs in HD people’s brains cannot
make necessary levels of BDNF.
As a result, for the Phase I MSC BDNF trial, the HD team
will make batches of MSCs from bone marrow cells provided
by a healthy donor and therefore containing normal, nondisease-causing huntingtin.
Federal regulations require GMP for any substance that will
be tested in humans. Thus, in the run-up to Phase I, the
MSC batches will be made at the UC Davis Institute for
Regenerative Cure’s GMP facility. It could make enough
MSCs for 100 patients, Dr. Nolta said.
“You need your own facility to get up to this scale,” she
commented. “How to manufacture these batches of cells is a
whole industry in and of itself. It’s usually companies that
would do this. Sometimes they charge exorbitant fees.”
This level of “scale-up” to a clinical trial is “our forte here,”
Dr. Nolta told me in our recent interview. The National
Institutes of Health and insurance companies don’t fund
these kinds of initiatives, she noted, leading many drug
candidates with good potential to “fall into the valley of
death.”
curehd.blogspot.com/2012/08/california-stem-cell-agency-approves-19.html
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During my visit to the IRC, she referred to the GMP as a
“super, super clean place.” It will triple-check the quality of
the MSCs.
As explained to me by GMP specialist Bill Gruenloh, normal
air contains hundreds of millions of particles per cubic foot.
Air handlers and HEPA filters reduce the number of
particles in the manufacturing room to only 10,000. Areas
under tissue culture hoods have just 100. In addition, the
highly specialized GMP employees maintain meticulous
records of every article in the facility. A computer constantly
monitors the GMP, and the employees double-check
readings with hand-held instruments. Thus no microorganisms are present in critical areas of the GMP.
If a contamination or other problem occurs with a test drug,
the GMP records help trace the cause, Gruenloh said.

UC Davis GMP specialist John Walker at work (photo by Gene Veritas)

The GMP also stores stem cells and other items at carefully
controlled, very low temperatures. The UC Davis GMP
developed the first GMP-grade cell-sorter in the world,
Gruenloh added.
In addition, the GMP houses its own quality control lab to
check the safety of products and verify that they are free of
contaminants and bacteria.
Putting the project in perspective
As Dr. Nolta has pointed out on several occasions, more than
10,000 patients worldwide have already received MSCs
infused into the blood stream. In fact, the drug regulatory
agencies of Canada and New Zealand have already approved
the use of MSCs to be prescribed as a drug to treat certain
diseases, although not yet HD. In addition, at least four
companies are currently testing MSCs or MSC-like cells in
clinical trials for other neurodegenerative conditions.
As always, we need to recall that only 10 percent of clinical
trials ever lead to an actual drug. Mathematically speaking,
curehd.blogspot.com/2012/08/california-stem-cell-agency-approves-19.html
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the odds are stacked against the Nolta-Wheelock project.
Even if the Phase I trial proves a dramatic success, the UC
Davis team will need to find ways to fund Phases II and III,
which will require larger numbers of participants and thus
cost more money. Backed by public bonds, CIRM will run
out of money in about four years, unless the agency can
attract private investors. At least for now, the state of
California’s dire fiscal situation makes further public funding
unlikely, although one cannot predict the mood of the voters.
With an eye to the future, Dr. Nolta and UC Davis have
secured a patent for the MSC siRNA delivery technology in
the hopes that a pharmaceutical firm or other private
investor might risk supporting further research and testing
in exchange for some of the potential profits from a drug.
She noted that companies visit the IRC regularly, although
none has yet expressed an interest in supporting HD work.
Despite these caveats, I am struck by the apparent simplicity
of the UC Davis approach: using human cells as a way to
deliver remedies to the brain.
I am also impressed with the UC Davis team’s boldness in
moving as quickly as possible towards a clinical trial. In fact,
some scientists think they’re moving too quickly with their
siRNA plans, although Dr. Nolta characterized their
criticism as a “misunderstanding” of her project, since it is
the BDNF trial, not the siRNA, that is moving toward the
clinic first. The siRNA studies are only in early rodent
testing.
A successful MSC HD trial would extend immense hope to
patients suffering from other neurological diseases (such as
Alzheimer’s and Parkinson’s), as well as ischemia, heart
disease, and other conditions, Dr. Nolta said. Such hope
would likely translate into greater private funding for MSC
research.
Hope, realism, and future advocacy
California’s HD stem cell advocates – along with fellow HD
activists around the world – can feel confident that CIRM is
having an important impact on HD research.
We now await the MSC trial results – and with great hope!
However, we should also proceed with patience and realism.
Science takes time.
Furthermore, most scientists think that treating HD
successfully will require a cocktail of remedies, not just one.
curehd.blogspot.com/2012/08/california-stem-cell-agency-approves-19.html
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With grassroots support for, and intense interest in, the UC
Davis HD program, the HD community is betting heavily
that MSCs will provide a way to alleviate the conditions’
horrific symptoms.
Judging from the unprecedented excitement about the
CIRM grant that I have witnessed in the HD Facebook
community in comparison with news about other
breakthroughs, I think people perceive stem cells as
providing the greatest hope. Indeed, for many Americans,
stem cells seem to hold an almost magical appeal, as they
once did for the young Jan Nolta at the start of her career.
People seem to sense viscerally that they can provide cures
and replace lost cells and tissues. Could stem cells represent
our new Fountain of Youth?
Naturally, we all want, need, and deserve to celebrate the
CIRM award.
I myself have advocated for California stem cell research for
more than a decade through HDSA-San Diego. Having lost
my mother to HD in 2006 at the age of 68 and tested
positive for HD in 1999, I anxiously await treatments. When
people told me that potential stem cell breakthroughs lay too
far in the future to offer me hope, my resolve to fight only
strengthened.
Yet we should also keep in mind that scientists are working
just as hard on numerous other, highly important
approaches. They don’t stir the controversy and publicity
that have surrounded stem cells, and many are extremely
difficult to understand, but they could very well lead to
effective treatments.
In effect, the Nolta-Wheelock project is another “shot on
goal” in the search for HD treatments. The CHDI
Foundation,Inc., the major private backer of HD drug
research, and its collaborators will attempt as many as eight
such shots in the next few years. The more shots, the better
the chances of finding treatments and a cocktail.
In the meantime, just as Dr. Nolta, the UC Davis team, and
scientists around the world work feverishly to liberate us
from HD, we in the HD community must continue to
strategically advocate for our cause, creatively help change
the course of science, and participate in the crucial research
studies and clinical trials that provide the key to defeating
HD.
***
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Once the UC Davis trial is approved the FDA, details of how
to participate will become available at www.clinicaltrials.gov.
For an HD family member’s account of the historic CIRM
meeting, read Katie Jackson’s report at The Huntington’s
Post.
To learn more about Dr. Nolta’s research, read an article by
Dr. Marsha Miller by clicking here.
For the official CIRM evaluation of the project, please click
here.
For in-depth reporting on CIRM’s activities, see California
Stem Cell Report.
You can also read an impassioned defense of stem cell
research by global HD advocate Charles Sabine.
HD scientist Dr. Elena Cattaneo provides an update on the
European Union’s support for stem cell research.
For an overview of stem cells, see Stem Cells for Dummies.
On stem cells and HD, also see www.HDBuzz.net.
To see a presentation by Dr. Nolta on MSCs and HD, watch
the video below.

Towards Stem-Cell Treatments for
Huntington's Disease: Talk by Dr. Jan
Nolta
from Gene Veritas
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Towards Stem-Cell Treatments for Huntington's Disease: Talk by Dr. Jan
Nolta from Gene Veritas on Vimeo.
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Labels: advocate , antisense , BDNF , brain , CHDI , CIRM , clinical trial , cocktail ,
drug , gene therapy , huntingtin , Huntington's , mesenchymal stem cell ,
neurodegenerative , RNA interference , siRNA , stem cell , striatum

1 comment:
curehd.blogspot.com/2012/08/california-stem-cell-agency-approves-19.html

15/16

11/18/21, 10:32 AM

At Risk for Huntington's Disease: California stem cell agency approves $19 million clinical trial project as Huntington’s disease f…

stemcelltherapy said...
There is no doubt that medical science has achieved a number
of mile stones, especially at the time of emergency but at the
same time it is also true that its medication has a number of
side effects. So at that moment stem cell therapy can be
considered as a perfect solution that to without any medication.
Thank you.
stem cell center
1:30 AM, February 19, 2013
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